ChosenMed Technology Files for IPO Following Strategic Investment from Yangtze Delta Region Institute of Tsinghua University

VCBeat (WeChat ID: vcbeat) has learned that in June 2018, Qiuzhen Medical Technology (Beijing) Co., Ltd. (hereinafter referred to as “Qiuzhen Medical”) announced it had secured strategic investment from Hangzhou Shuimu Fenghua Venture Capital Fund, which is affiliated with the Zhejiang Yangtze Delta Region Institute of Tsinghua University. Capital from the Tsinghua University ecosystem will support Qiuzhen Medical’s expansion across the entire oncology industry chain. Qiuzhen Medical will invest RMB 100 million in phased construction of its Zhejiang-based production base for in vitro diagnostic reagents and equipment.

Dr. Zhou Qiming, President of Qiuzhen Medical, stated that the company would take this collaboration as an opportunity to leverage Zhejiang’s policy advantages and Tsinghua University’s strengths in talent and technology, thereby accelerating the registration and filing of tumor in vitro diagnostic kits and GMP-compliant production for its subsidiaries. Many members of the Qiuzhen Medical team have studied or worked at Tsinghua University. Upholding the Tsinghua motto of “Self-Discipline and Social Commitment,” the Qiuzhen team remains committed to exploring technological innovation and advancing medical excellence, with the ultimate goal of promoting public health and well-being.

Li Xiaofeng, Vice President of the Hangzhou Branch of the Yangtze Delta Region Institute of Tsinghua University, stated: “The Qiuzhen Medical team is characterized by its passion and pragmatic approach. We believe that Qiuzhen Medical can leverage the resources and platform advantages of the Institute to achieve rapid growth in the oncology testing industry, accelerate the clinical registration of projects, and facilitate the translation of research outcomes. We look forward to this collaboration realizing the shared vision of both parties.”

Zhejiang Provincial Institute of Tsinghua University is a research institution jointly established by the People’s Government of Zhejiang Province and Tsinghua University, guided by the spirit of complementary advantages and mutual development. It operates as a public institution under enterprise-style management. Leveraging Tsinghua University’s scientific and technological expertise and talent pool, the Institute serves as a renowned mainland China platform for technological innovation and a base for research commercialization, rooted in Zhejiang and oriented toward the Yangtze River Delta region. It is committed to advancing technological innovation, providing technical services, cultivating talent, and promoting the industrialization of high-tech achievements. In doing so, it aims to better fulfill Tsinghua University’s social service mission, facilitate the transformation of economic and social development models in the Yangtze River Delta, and make positive contributions to achieving scientific, harmonious, and leading-edge development.

Qiuzhen Medical is a state-participated mixed-ownership enterprise group and a member unit of the National Medical Big Data Center. Committed to becoming a global leader in providing full-process products and services for precision oncology, its product portfolio covers early cancer screening, prevention and diagnosis, dynamic monitoring, medication guidance, prognosis assessment, and bioinformatics big data analysis.